Results of the Phase 3 Study of Lenalidomide Versus Placebo As Maintenance Therapy Following Second-Line Treatment for Patients with Chronic Lymphocytic Leukemia (the CONTINUUM Trial)

被引：4
|
作者：
Foa, Robin [1 ]
Schuh, Anna [2 ]
Zaritskey, Andrey [3 ]
Semochkin, Sergey [4 ]
Simpson, David [5 ]
Egyed, Miklos [6 ]
Vokurka, Samuel [7 ]
Kassis, Jeannine [8 ]
Zhang, Jennie [9 ]
Purse, Brendan [9 ]
Chanan-Khan, Asher A. [10 ]
机构：
[1] Univ Sapienza, Policlin Umberto 1, Rome, Italy
[2] Univ Oxford, Oxford, England
[3] St Petersburg State Med Univ, St Petersburg, Russia
[4] Pirogov Russian Natl Res Med Univ, Moscow, Russia
[5] North Shore Hosp, Auckland, New Zealand
[6] Kaposi Mor Teaching Hosp, Dept Internal Med, Kaposvar, Hungary
[7] Univ Hosp Plzen, Plzen, Czech Republic
[8] Hop Maison Neuve Rosemont, Montreal, PQ, Canada
[9] Celgene Corp, Summit, NJ USA
[10] Mayo Clin, Div Hematol, Jacksonville, FL USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.230.230
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
230
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice
    Breccia, Massimo
    Abruzzese, Elisabetta
    Castagnetti, Fausto
    Bonifacio, Massimiliano
    Gangemi, Domenica
    Sora, Federica
    Iurlo, Alessandra
    Luciano, Luigiana
    Gozzini, Antonella
    Gentile, Massimo
    Bocchia, Monica
    Luzi, Debora
    Maggi, Alessandro
    Sgherza, Nicola
    Isidori, Alessandro
    Crugnola, Monica
    Pregno, Patrizia
    Scortechini, Anna Rita
    Capodanno, Isabella
    Pizzuti, Michele
    Foa, Robin
    ANNALS OF HEMATOLOGY, 2018, 97 (09) : 1577 - 1580
  • [32] Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
    Breccia, Massimo
    Alimena, Giuliana
    BIODRUGS, 2011, 25 (03) : 147 - 157
  • [33] Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
    Massimo Breccia
    Giuliana Alimena
    BioDrugs, 2011, 25 : 147 - 157
  • [34] Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice
    Massimo Breccia
    Elisabetta Abruzzese
    Fausto Castagnetti
    Massimiliano Bonifacio
    Domenica Gangemi
    Federica Sorà
    Alessandra Iurlo
    Luigiana Luciano
    Antonella Gozzini
    Massimo Gentile
    Monica Bocchia
    Debora Luzi
    Alessandro Maggi
    Nicola Sgherza
    Alessandro Isidori
    Monica Crugnola
    Patrizia Pregno
    Anna Rita Scortechini
    Isabella Capodanno
    Michele Pizzuti
    Robin Foà
    Annals of Hematology, 2018, 97 : 1577 - 1580
  • [35] Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib
    Radich, Jerald P.
    Hochhaus, Andreas
    Giles, Francis J.
    Ross, David M.
    Saglio, Giuseppe
    Hughes, Timothy P.
    Kim, Dong-Wook
    Fellague-Chebra, Rafik
    Sondhi, Manu
    Tiwari, Ranjan
    Mishra, Kaushal
    Mahon, Francois-Xavier
    BLOOD, 2019, 134
  • [36] Second-line Therapy and Beyond Resistance for the Treatment of Patients With Chronic Myeloid Leukemia Post Imatinib Failure
    Jabbour, Elias
    Cortes, Jorge E.
    Kantarjian, Hagop
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S272 - S279
  • [37] Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II Trial
    Flinn, Ian W.
    Mainwaring, Mark
    Peacock, Nancy
    Shipley, Dianna
    Arrowsmith, Edward
    Savona, Michael R.
    Hainsworth, John D.
    Berdeja, Jesus G.
    BLOOD, 2012, 120 (21)
  • [38] Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials
    Joffe, Erel
    Goldschmidt, Neta
    Bairey, Osnat
    Fineman, Riva
    Ruchlemer, Rosa
    Rahimi-Levene, Naomi
    Shvidel, Lev
    Greenbaum, Uri
    Aviv, Ariel
    Tadmor, Tamar
    Braester, Andrea
    Arad, Ariela
    Polliack, Aaron
    Herishanu, Yair
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 101 (03) : 399 - 406
  • [39] COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER INATINIB FAILURE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS
    Tiribelli, M.
    Bonifacio, M.
    Binotto, G.
    Maino, E.
    Calistri, E.
    De Marchi, F.
    Scaffidi, L.
    Frison, L.
    Medeot, M.
    Ambrosetti, A.
    Semenzato, G.
    Fanin, R.
    HAEMATOLOGICA, 2015, 100 : 132 - 132
  • [40] A Phase II Study of the Combination of Lenalidomide and Rituximab in Patients with Treatment-NaiVe and Relapsed Chronic Lymphocytic Leukemia
    Strati, Paolo
    Thompson, Philip A.
    Keating, Michael
    Hinojosa, Christina
    Rodriguez, Diana
    Wang, Xuemei
    Daver, Naval G.
    Jain, Nitin
    Burger, Jan A.
    Estrov, Zeev
    Wierda, William G.
    Kantarjian, Hagop M.
    Obrien, Susan
    Ferrajoli, Alessandra
    BLOOD, 2016, 128 (22)
12345